<!DOCTYPE html>
<html lang="en">
  <head>
            
   

<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<meta http-equiv="X-UA-Compatible" content="ie=edge" />

<link rel="shortcut icon" href="/wiki/assets/favicon.ico" type="image/x-icon" />

<title>Perioperative Management of Von Willebrand Disease Vwd Vwf • Kang Rui Xiang's Notes</title>

<meta name="description" content="This is my wiki page" />

<meta property="og:title" content="Perioperative Management of Von Willebrand Disease Vwd Vwf • Kang Rui Xiang's Notes" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://kangruixiang.github.io/wiki//notes/perioperative management of von willebrand disease vwd vwf/" />
<meta property="og:image" content="/assets/avatar.png" />
<meta property="og:description" content="This is my wiki page" />

<link rel="canonical" href="https://kangruixiang.github.io/wiki//notes/perioperative management of von willebrand disease vwd vwf/" />

<link rel="stylesheet" href="/wiki/style.css" />

<style>
  @font-face {
    font-family: "Concourse";
    src: url("/wiki/assets/fonts/concourse_3_regular.woff2") format("woff2");
    font-style: normal;
  }
  @font-face {
    font-family: "Equity";
    src: url("/wiki/assets/fonts/equity_a_regular.woff2") format("woff2");
    font-style: normal;
  }
</style>

  </head>
  <body class="h-screen bg-ember scroll-smooth">
    <div
      class="fixed top-0 w-screen"
    >
    <div class="flex items-center justify-between max-w-4xl px-4 py-4 mx-auto md:px-10 bg-ember bg-opacity-90">
     <a href="/wiki/"> <svg xmlns="http://www.w3.org/2000/svg" class="w-8 h-8" viewBox="0 0 20 20" fill="currentColor">
  <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z" />
</svg></a>

      <nav class="flex space-x-2 font-semibold uppercase">
        <a href="/wiki/" class="p-4 rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Home</a
        >
        <a
          href="/wiki/notes/Step 1"
          class="p-4 font-semibold rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Step 1</a
          >
      </nav>
    </div>
    </div>

    <div class="flex items-center justify-center flex-none max-w-4xl px-6 mx-auto mt-32 mb-32">
      <div  class="font-serif prose prose-lg prose-h1:text-xl prose-h2:text-lg md:prose-2xl md:prose-h1:text-4xl md:prose-h2:text-3xl prose-hr:border-zinc-900 hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200"><h1 id="perioperative-management-of-von-willebrand-disease-vwd-vwf" tabindex="-1">perioperative management of von willebrand disease vwd vwf</h1>
<ul>
<li>related: <a href="/wiki/notes/Hemeonc/">Hemeonc</a>, <a href="/wiki/notes/Perioperative/">Perioperative</a></li>
<li>tags: #hemeonc</li>
</ul>
<hr>
<p><img src="https://photos.thisispiggy.com/file/wikiFiles/20220812152833.png" alt=""></p>
<p><strong>Von Willebrand disease</strong> (VWD) is the most common inherited bleeding disorder.  <strong>Type 1 VWD</strong> accounts for 75% of cases and is marked by a <strong>quantitive deficiency</strong> of von Willebrand factor (VWF), leading to low VWF antigen, VWF activity, and factor VIII levels.  Patients with blood type O have VWF levels that are up to 30% lower than those with blood types A, B, or AB.</p>
<p>Most patients (99%) with VWD have mild or asymptomatic disease and never seek clinical attention.  However, clinically significant skin and mucosal bleeding can occur.  Treatment of bleeding complications is typically achieved with:</p>
<ul>
<li><strong>Desmopressin</strong> (DDAVP) - an antidiuretic hormone analogue that increases VWF and factor VIII levels and used primarily for mild bleeding episodes or prior to minor procedures.  DDAVP is effective for <strong>mild/moderate</strong> type 1 VWD, but those with severe bleeding (such as this patient who required cauterization) often do not respond sufficiently <strong>(Choice C)</strong>.</li>
<li><strong>VWF preparations</strong> - used in <strong>severe bleeding</strong> episodes in those who do not respond to desmopressin and perioperatively for <strong>invasive surgeries</strong> (such as neurosurgery).  Several different preparations, including intermediate-purity factor VIII concentrates, high-purity VWF concentrate, and recombinant VWF, are available.
In this patient who has had severe bleeding and is preparing for neurosurgery, administration of VWF preparations will likely lead to VWF activity levels close to 100% and is the most effective strategy to prevent perioperative bleeding.</li>
</ul>
<p>Aminocaproic acid is an anti-fibrinolytic agent that is sometimes used for patients with VWD who have menorrhagia or mild mucosal bleeding; it is usually used in combination with other therapies.</p>
<p>Cryoprecipitate is not routinely used for VWD due to the risk of viral transmission; VWF preparations are the preferred therapy for more serious bleeding or prior to a major procedure.</p>
<p>Platelets contain a small proportion of total blood VWF and can be used in patients who have refractory bleeding with VWF concentrates.</p>

      </div>
    </div>
    
     <div class="fixed hidden ml-8 right-[5%] 2xl:block top-48 border-l-2 border-zinc-600 px-2"> 
        
      </div>


    <div class="max-w-4xl p-2 mx-auto font-sans font-semibold uppercase bg-emberdark">Backlinks</div>
    <div class="mx-auto font-serif prose prose-lg hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200">
      
      <!-- <hr /> -->



<ul>
  
  <li>
    <div class="">
      <a href="/wiki//notes/Hemeonc/" class="peer">Hemeonc</a>
      <div
        role="none"
        class="absolute hidden px-8 py-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-ember prose-headings:hidden prose-hr:hidden"
      >
        <h1 id="hemeonc" tabindex="-1">Hemeonc</h1>
<ul>
<li>Keywords:: <a href="/wiki/notes/Step%203/">Step 3</a>, <a href="/wiki/notes/Medicine/">Medicine</a></li>
</ul>
<hr>
<h2 id="mksap" tabindex="-1">MKSAP</h2>
<ul>
<li><a href="/wiki/notes/management%20of%20bone%20metastasis/">management of bone metastasis</a></li>
<li><a href="/wiki/notes/Hematopoietic%20Stem%20Cells%20and%20Their%20Disorders/">Hematopoietic Stem Cells and Their Disorders</a></li>
<li><a href="/wiki/notes/Multiple%20Myeloma%20and%20Related%20Disorders/">Multiple Myeloma and Related Disorders</a></li>
<li><a href="/wiki/notes/Erythrocyte%20Disorders/">Erythrocyte Disorders</a></li>
<li><a href="/wiki/notes/Iron%20Overload%20Syndromes/">Iron Overload Syndromes</a></li>
<li><a href="/wiki/notes/Platelet%20Disorders/">Platelet Disorders</a></li>
<li><a href="/wiki/notes/MKSAP%20Bleeding%20Disorders/">MKSAP Bleeding Disorders</a></li>
<li><a href="/wiki/notes/MKSAP%20Transfusion%20Medicine/">MKSAP Transfusion Medicine</a></li>
<li><a href="/wiki/notes/Thrombotic%20Disorders/">Thrombotic Disorders</a></li>
<li><a href="/wiki/notes/Hematologic%20Issues%20in%20Pregnancy/">Hematologic Issues in Pregnancy</a></li>
<li><a href="/wiki/notes/Issues%20in%20Oncology/">Issues in Oncology</a></li>
<li><a href="/wiki/notes/Breast%20Cancer/">Breast Cancer</a></li>
<li><a href="/wiki/notes/Ovarian%20Cancer/">Ovarian Cancer</a></li>
<li>[[M</li>
</ul>

      </div>
    </div>
  </li>
  
</ul>


</div>

    <footer>
      <div class="max-w-6xl mx-auto mb-10 text-sm text-center mt-96">
        By Kang Rui Xiang
      </div>
      </div>
    </footer>
  </body>
</html>
